References
1. Василевская Л.Н. Предраковые заболевания и начальные формы рака шейки матки // Василевская Л.Н., Винокур М.Л.,
Никитина Н.И., М.: Медицина: 2011. С.4-23. [Vasilevskaya L.N. Precancerous diseases and initial forms of cervical cancer //
Vasilevskaya L.N., Vinokur M.L., Nikitina N.I., M.: Medicine: 2011. pp.4-23.]
2. Волков В.Г. Современные возможности лечения папилломавирусной инфекции шейки матки // Волков В.Г., Захарова Т.
В. Вестник новых медицинских технологий. 2020.- т.7 № 2. - С. 79-81.[Volkov V.G. Modern possibilities of treatment of pa
pillomavirus infection of the cervix // Volkov V.G., Zakharova T.V. Bulletin of new medical technologies. 2020.- vol.7 No. 2. -
pp. 79-81.]
3. Гузенко Н.Н. Диагностика папилломавирусной инфекции человека (ВПЧ) и ее клиническое значение // Гузенко Н.Н. Ак
туальные проблемы здравоохранения областей Центральной России: сборник науч. тр.-Липецк, 2021. - Ч.1.- С.181-183.
[Guzenko N.N. Diagnostics of human papillomavirus infection (HPV) and its clinical significance // Guzenko N.N. Actual pro
blems of healthcare in the regions of Central Russia:collection of scientific tr.-Lipetsk, 2021. - Part 1.- pp.181-183.
4. Дубенский В.В. Урогенитальная папилломавирусная инфекция // Дубенский В.В. Российский журнал кожных и венери
ческих болезней. - 2015.- №5. - С.50-55. [Dubensky V.V. Urogenital papillomavirus infection // Dubensky V.V. Russian Journal
of Skin and Venereal Diseases.- 2015.- No.5. - pp.50-55.
5. Клинико-морфологические аспекты цервикальной папилломавирусной инфекции / Л. Ф. Коломиец, Л. Н. Уразова, Н. В.
Севастьянова, О. Н. Чуруксаева // Вопр. онкол. -2022. -Т.48, №1. - С.43-46. [Clinical and morphological aspects of cervical
papilloma virus infection / L. F. Kolomiets, L. N. Urazova, N. V. Sevastyanova, O. N. Churuksaeva // Vopr. oncol. -2022. -Vol.
48, No. 1. - pp.43-46.]
6. Козаченко В.П. / Диагностика и лечение эпителиальных дисплазий и преинвазивной карциномы шейки матки // Козаченко
В.П. Клин. лекции под ред. В. Н. Прилепской 2-е изд. М.: МЕДпресс, 2000. - С. 139-152. [Kozachenko V.P. / Diagnosis and
treatment of epithelial dysplasia and preinvasive cervical carcinoma // Kozachenko V.P. Clinical lectures edited by V. N. Prileps
kaya 2nd ed. M.: MEDpress, 2000. - Pp. 139-152.
7. Козаченко В.П. Современное состояние проблемы рака шейки матки // Козаченко В.П. Клин. лекции под ред. В.Н. При
лепской 2-е изд. // М.:МЕДпресс: 2000. - С.133-138. [Kozachenko V.P. The current state of the problem of cervical cancer //
Kozachenko V.P. Klin. lectures edited by V. N. Prilepskaya 2nd ed. // Moscow:MEDpress: 2000. - pp.133-138.
8. Коломиец Л. А. Генитальная папилломавирусная инфекция и рак шейки матки // Коломиец Л.А., Уразова Л.Н. Томск:
НТЛ, 2002. 100 с.[Kolomiets L. A. Genital papillomavirus infection and cervical cancer // Kolomiets L.A., Urazova L.N. Tomsk:
NTL, 2002. 100 p.]
9. Кустаров В.Н. Патология шейки матки // Кустаров В.Н., Линде В.А. СПб.: Изд. «Гиппократ», 2002. 144 с. [Kustarov
V.N. Pathology of the cervix // Kustarov V.N., Linde V.A. St. Petersburg: Publishing house "Hippocrates", 2002. 144 p.]
10. Ландеховский Ю.Д. Хирургическое лечение лейкоплакии шейки матки // Ландеховский Ю.Д., Бабичева И.А. Клин, лек
ции под ред. В.Н. Прилепской. 2-е изд.- М.:МЕДпресс 2000. - С.94-107. [Landekhovsky Yu.D. Surgical treatment of cervical
leukoplakia // Landekhovsky Yu.D., Babicheva I.A. Klin, lectures edited by V.N. Prilepskaya. 2nd ed.- Moscow: MEDpress 200
0. - pp.94-107.]
11. Манухин И.Б. Клиника, диагностика и лечение генитального герпеса у женщин //Манухин И.Б., Захарова Т.П. Клин, лек
ции под ред. В.Н. Прилепской 2-е изд.- М.:МЕДпресс 2000.- С. 229-239. [Manukhin I.B. Clinic, diagnosis and treatment of
genital herpes in women // Manukhin I.B., Zakharova T.P. Klin, lectures edited by V.N. Prilepskaya 2nd ed. - M.: MEDpress 20
00.- pp. 229-239.]
12. Марченко Л.A. Современные клинические аспекты эпидемиологии генитального герпеса // Марченко Л.А.Клин, лекции
под ред. В.Н. Прилепской 2-е изд.-М.: МЕДпресс 2000. - С.220-228.[Marchenko L.A. Modern clinical aspects of epidemiology
of genital herpes // Marchenko L.A. Klin, lectures edited by V.N. Prilepskaya 2nd ed.-M.: MEDpress 2000. - pp.220- 228.]
13. Полякова В.А. Онкогинекология //Полякова В.А. Москва:Изд-во «Медицинская книга», 2001. - С.66-105.[Polyakova V.A.
Oncogynecology // Polyakova V.A. Moscow: Publishing house "Medical Book",2001. - pp.66-105.]
14. Рак репродуктивных органов: эпидемиология, факторы риска / Писарева Л.Ф., Мельник А.А., Одинцова И.Н., Мартынова Н.А. // Сибирский онкологический журнал. - 2003 №1. - С.56-69.[Cancer of reproductive organs: epidemiology, risk factors Pisareva L.F., Melnik A.A., Odintsovo I.N., Martynova N.A. // Siberian Oncological Journal. - 2003 No. 1. - pp.56-69.]
15. Роль папилломавирусной инфекции в онкогинекологической патологии / Сафронникова Н.Р., Вишневский А. С., Мера
бишвили В.М. // Сб. Новые информационные технологии в онкологической статистике.- СПб.: 2021. - С.204-205.[The
role of papillomavirus infection in oncogynecological pathology / Safronnikova N.R., Vishnevsky A.S., Merabishvili V.M. // Col
lection of New information technologies in oncological statistics.- St. Petersburg: 2021. - pp.204-205.]
16. Трубина Т.Б. / Особенности диагностики и лечения фоновых и предраковых заболеваний шейки матки у женщин, пере
несших медицинский аборт // Трубина Т.Б. Здравоохранение Башкортостана, 2018. - №4. - С.59-61.[Trubina T.B. / Features
of diagnosis and treatment of back ground and precancerous diseases of the cervix in women who have undergone medical
abortion // Trubina T.B. Health care of Bashkortostan, 2018. - No. 4. - pp.59-61.]
17. Фролова И.И. Клинико-морфологические исследования дискератозов и предрака шейки матки // Фролова И.И., Бабиченко И.И. / Вопросы гинекологии, акушерства и перинатологии. - 2019. - т.2, №3.- С. 19-24.[Frolova I.I. Clinical and morphological studies of dyskeratoses and precancerous cervix // Frolova I.I., Babichenko I.I. / Questions of gynecology, obstetrics and perinatology. - 2019. - vol.2, No. 3.- pp. 19-24.]
18. Шаймарданова Г.И. Клинические проявления папилломавирусной инфекции гениталий у женщин. // Шаймарданова Г.
И., Савичева A.M., Максимов С.Я. Журнал акушерства и женских болезней. - 2021. Выпуск 2., том XLX - С.14-18. [Shai
mardanova G.I. Clinical manifestations of genital papillomavirus infection in women. // Shaimardanova G.I., Savicheva A.M.,
Maksimov S.Ya. Journal of Obstetrics and women's diseases. - 2021. Issue 2., volume XLX - p.14-18.
19. Шериз Ж. Профилактика рака шейки матки в районах с недостаточным обеспечением ресурсами здравоохранения //
Шериз Ж., Хердман К. Точка зрения. - перев. 2020.- т. 18 №1. - С. 1-7. [Sheriz Zh. Prevention of cervical cancer in areas with in sufficient provision of health resources // Sheriz J., Herdman K. Point of view. - transl. 2020. - vol. 18 No. 1. - pp. 1-7.]
20. Alphs H.H., Wu T.C., Roden R.B.S. Prevention and treatment of cervical cancer by vaccination. In: Bovicelli A, Giordano A,
Kurman RJ (eds.), Molecular pathology of gynecology cancer, Humana Press, Totowa, New Jersey, 2017;124–154.
21. Altobelli E., Lattanzi A. Cervical Carcinoma in the European Union: An Update on Disease Burden, Screening Program State of
Activation, and Coverage as of March 2014. Int. J. Gynecol. Cancer 2015, 474-483.
22. Anttila A., Ronco G. Description of the national situation of cervical cancer screening in the member states of the European
Union. Eur. J. Cancer 2019, 45, 2685-2708.
23. Apgar B.S., Kaufman A.J., Bettcher C. Gynecologic procedures:colposcopy, treatments for cervical intraepithelial neoplasia and
endometrial assessment. Am Fam Physician. 2018;87(12):836-43.
24. Asciutto K.C., Henic E., Darlin L. Follow up with HPV test and cytology as test of cure, 6 months after conization, is reliable.
Acta Obstet. Gynecol. Scand. 2016, 95,1251-1257.
25. Ayinde O.A., Omigbodun A.O., Ilesanmi A.O. Awareness of cervical cancer, Papanicolaou's smear and its utilisation among fema
le undergraduates in Ibadan. Afr J Reprod Health. 2017;8(3):68-80.
26. Bassal R., Schejter E., Bachar R. Recent trends of cervical cancer and Cervical Intraepithelial Neoplasia 3 (CIN3) in Israel.
Arch.Gynecol. Obstet. 2015, 292, 405-413.
27. Basu P., Meheus F., Chami Y. Management algorithms for cervical cancer screening and precancer treatment for resource-limited
settings. Int. J. Gynecol. Obstet.2017, 26-32.
28. Blumenthal P.D., Lauterbach M., Sellors J.W. Training for cervical cancer prevention programs in low-resource settings: focus
on visual inspection with acetic acid and cryotherapy. Int J Gynaecol Obstet Off Organ Int Fed Gynaecol Obstet. 2017;89 Suppl
2:S30-7.
29. Boiron, L., Joura E., Largeron N. Estimating the cost-effectiveness profile of a universal vaccination programme with a nine-
valent HPV vaccine in Austria. BMC Infect. Dis. 2016,16,153.
30. Boonlikit S. Correlation between Reid’s colposcopic index and histologic results from colposcopically directed biopsy in differ
entiating high-grade from low-grade squamous in traepithelial lesion at Rajavithi Hospital, Med Assoc Thai, 2021; 94(Suppl.2):
S59–65.
31. Borena W., Grunberger M., Widschwendter. Pre-vaccine eracervical human papillomavirus infection among screening population
of women in west Austria. BMC Public Health 2016,16, 889.
32. Bornstein J., Bentley J., Bosze P. Colposcopic terminology of the International Federation for Cervical Pathology and Colposcopy. Obstet Gynecol. 2022;120:166-72.
33. Campbell C., Kafwafwa S., Brown H. Use of thermo-coagulation as an alternative treatment modality in a ’screen and treat’ pro
gramme of cervical screening in rural Malawi. Int J Cancer 2016; 139:908-15.
34. Campos N.G., Maza M., Alfaro K. The comparative and cost-effectiveness of HPV- based cervical cancer screening algorithms
in El Salvador. Int J Cancer 2015;137:893-902.
35. Castanon A., Landy R., Cuzick J. Cervical Screening at Age 50-64 Years and the Risk of Cervical Cancer at Age 65 Years and
Older: Population-Based Case Control Study. PLoS Med. 2019,11, e1001585.
36. Castle P.E., Smith K.M., Davis T.E. Reliability of the Xpert HPV assay to detect high-risk human papillomavirus DNA in a col
poscopy referral population. Am J Clin Pathol 2015;143: 126-33.
37. Chirenje Z.M., Rusakaniko S., Kirumbi L. Situation analysis for cervical cancer diagnosis and treatment in east, central and
southern African countries. Bull World Health Organ 2021;79:127-32.
38. Clarke B., Chetty R. Postmodern cancer: the role of humanimmunodeficiency virus in uterine cervical cancer. MolPathol MP.
2022;55(1):19-24.
39. Clifford G.M., Smith J.S., Plummer M. Human papillo mavirus types in invasive cervical cancer worldwide: a meta-analysis. Br
J Cancer. 2018;88(1):63-73.
40. Collins S., Mazloomzadeh S., Winter H. High incidence of cervical human papillomavirus infection in women during their first
sexual relationship. BJOG Int J Obstet Gynaecol.2022;109(1):96-8.
41. Costa S., Venturoli S., Origoni M. Performance of HPV DNA testing in the follow-up after treatment of high-grade cervical le
sions, adenocarcinoma in situ (AIS) and microinvasive carcinoma. Ecancermedicalscience 2015, 9, 528.
42. Cunningham M.S., Davison C., Aronson K.J.HPV vaccine acceptability in Africa:a systematic review.Prev Med. 2021;69:274-9.
43. Cuschieri K., Bhatia R., Cruickshank M. HPV testing in the context of post-treatment follow up (test of cure). J. Clin.Virol. 2016, 76, S. 56-S61.
44. Cuzick J., Szarewski A., Cubie H. et al. Management of women who test positive for high-risk types of human papillomavirus:
The HART study. Lancet 2023, 362,1871-1876.
45. Dalla Palma P., Giorgi Rossi P., Collina G. et al. The risk of false-positive histology according to the reason for colpos copy re
ferral in cervical cancer screening: a blind revision of all histologic lesions found in the NTCC trial. Am J Clin Pathol, 2018; 12
9(1): 75–80.
46. de Freitas A.C., Coimbra E.C., Leitao Mda C.G. Molecular targets of HPV oncoproteins: potential biomarkers for cervical car
cinogenesis. Biochim Biophys Acta. 2020;1845(2):91-103.
47. De Thurah L., Bonde J., Lam J.U.H. Concordant testing results between various human papillomavirus assays in primary cervical cancer screening: Systematic review. Clin.Microbiol. Infect. 2018,29-36.
48. Denny L., Quinn M., Sankaranarayanan R. Chapter 8: Screening for cervical cancer in developing countries. Vaccine.2016;24
Suppl 3:S3/71-7.
49. Dijkstra M.G., van Niekerk D., Rijkaart D.C. Primary hrHPVDNA Testing in Cervical Cancer Screening: How to Manage Screen-Positive Women? A POBASCAM Trial Substudy. Cancer Epidemiol. Biomarkers Prev. 2017, 23,55-63.
50. Dobson S.R.M., McNeil S., Dionne M. Immunogenicity of 2doses of HPV vaccine in younger adolescents vs 3 doses in
young women:a randomized clinical trial. JAMA.2018; 30 9(17):1793-802.
51. Eze J.N., Umeora O.U., Obuna J.A. Cervical cancer awareness and cervical screening uptake at the Mater Misericordiae Hospital, Afikpo, Southeast Nigeria. Ann Afr Med. 2022;11 (4):238-43.
52. Ezechi O.C.,Gab-Okafor C.V.,Ostergren P.O. Willingness and acceptability of cervical cancer screening among HIV positive
Nigerian women. BMC Public Health. 2018;13 (1):46.
53. Goldie S.J., Gaffikin L., Goldhaber-Fiebert J.D. et al. Cost-effectiveness of cervical-cancer screening in five developing countries. N Engl J Med. 2015;353(20):2158-68.
1. Василевская Л.Н. Предраковые заболевания и начальные формы рака шейки матки // Василевская Л.Н., Винокур М.Л.,
Никитина Н.И., М.: Медицина: 2011. С.4-23. [Vasilevskaya L.N. Precancerous diseases and initial forms of cervical cancer //
Vasilevskaya L.N., Vinokur M.L., Nikitina N.I., M.: Medicine: 2011. pp.4-23.]
2. Волков В.Г. Современные возможности лечения папилломавирусной инфекции шейки матки // Волков В.Г., Захарова Т.
В. Вестник новых медицинских технологий. 2020.- т.7 № 2. - С. 79-81.[Volkov V.G. Modern possibilities of treatment of pa
pillomavirus infection of the cervix // Volkov V.G., Zakharova T.V. Bulletin of new medical technologies. 2020.- vol.7 No. 2. -
pp. 79-81.]
3. Гузенко Н.Н. Диагностика папилломавирусной инфекции человека (ВПЧ) и ее клиническое значение // Гузенко Н.Н. Ак
туальные проблемы здравоохранения областей Центральной России: сборник науч. тр.-Липецк, 2021. - Ч.1.- С.181-183.
[Guzenko N.N. Diagnostics of human papillomavirus infection (HPV) and its clinical significance // Guzenko N.N. Actual pro
blems of healthcare in the regions of Central Russia:collection of scientific tr.-Lipetsk, 2021. - Part 1.- pp.181-183.
4. Дубенский В.В. Урогенитальная папилломавирусная инфекция // Дубенский В.В. Российский журнал кожных и венери
ческих болезней. - 2015.- №5. - С.50-55. [Dubensky V.V. Urogenital papillomavirus infection // Dubensky V.V. Russian Journal
of Skin and Venereal Diseases.- 2015.- No.5. - pp.50-55.
5. Клинико-морфологические аспекты цервикальной папилломавирусной инфекции / Л. Ф. Коломиец, Л. Н. Уразова, Н. В.
Севастьянова, О. Н. Чуруксаева // Вопр. онкол. -2022. -Т.48, №1. - С.43-46. [Clinical and morphological aspects of cervical
papilloma virus infection / L. F. Kolomiets, L. N. Urazova, N. V. Sevastyanova, O. N. Churuksaeva // Vopr. oncol. -2022. -Vol.
48, No. 1. - pp.43-46.]
6. Козаченко В.П. / Диагностика и лечение эпителиальных дисплазий и преинвазивной карциномы шейки матки // Козаченко
В.П. Клин. лекции под ред. В. Н. Прилепской 2-е изд. М.: МЕДпресс, 2000. - С. 139-152. [Kozachenko V.P. / Diagnosis and
treatment of epithelial dysplasia and preinvasive cervical carcinoma // Kozachenko V.P. Clinical lectures edited by V. N. Prileps
kaya 2nd ed. M.: MEDpress, 2000. - Pp. 139-152.
7. Козаченко В.П. Современное состояние проблемы рака шейки матки // Козаченко В.П. Клин. лекции под ред. В.Н. При
лепской 2-е изд. // М.:МЕДпресс: 2000. - С.133-138. [Kozachenko V.P. The current state of the problem of cervical cancer //
Kozachenko V.P. Klin. lectures edited by V. N. Prilepskaya 2nd ed. // Moscow:MEDpress: 2000. - pp.133-138.
8. Коломиец Л. А. Генитальная папилломавирусная инфекция и рак шейки матки // Коломиец Л.А., Уразова Л.Н. Томск:
НТЛ, 2002. 100 с.[Kolomiets L. A. Genital papillomavirus infection and cervical cancer // Kolomiets L.A., Urazova L.N. Tomsk:
NTL, 2002. 100 p.]
9. Кустаров В.Н. Патология шейки матки // Кустаров В.Н., Линде В.А. СПб.: Изд. «Гиппократ», 2002. 144 с. [Kustarov
V.N. Pathology of the cervix // Kustarov V.N., Linde V.A. St. Petersburg: Publishing house "Hippocrates", 2002. 144 p.]
10. Ландеховский Ю.Д. Хирургическое лечение лейкоплакии шейки матки // Ландеховский Ю.Д., Бабичева И.А. Клин, лек
ции под ред. В.Н. Прилепской. 2-е изд.- М.:МЕДпресс 2000. - С.94-107. [Landekhovsky Yu.D. Surgical treatment of cervical
leukoplakia // Landekhovsky Yu.D., Babicheva I.A. Klin, lectures edited by V.N. Prilepskaya. 2nd ed.- Moscow: MEDpress 200
0. - pp.94-107.]
11. Манухин И.Б. Клиника, диагностика и лечение генитального герпеса у женщин //Манухин И.Б., Захарова Т.П. Клин, лек
ции под ред. В.Н. Прилепской 2-е изд.- М.:МЕДпресс 2000.- С. 229-239. [Manukhin I.B. Clinic, diagnosis and treatment of
genital herpes in women // Manukhin I.B., Zakharova T.P. Klin, lectures edited by V.N. Prilepskaya 2nd ed. - M.: MEDpress 20
00.- pp. 229-239.]
12. Марченко Л.A. Современные клинические аспекты эпидемиологии генитального герпеса // Марченко Л.А.Клин, лекции
под ред. В.Н. Прилепской 2-е изд.-М.: МЕДпресс 2000. - С.220-228.[Marchenko L.A. Modern clinical aspects of epidemiology
of genital herpes // Marchenko L.A. Klin, lectures edited by V.N. Prilepskaya 2nd ed.-M.: MEDpress 2000. - pp.220- 228.]
13. Полякова В.А. Онкогинекология //Полякова В.А. Москва:Изд-во «Медицинская книга», 2001. - С.66-105.[Polyakova V.A.
Oncogynecology // Polyakova V.A. Moscow: Publishing house "Medical Book",2001. - pp.66-105.]
14. Рак репродуктивных органов: эпидемиология, факторы риска / Писарева Л.Ф., Мельник А.А., Одинцова И.Н., Мартынова Н.А. // Сибирский онкологический журнал. - 2003 №1. - С.56-69.[Cancer of reproductive organs: epidemiology, risk factors Pisareva L.F., Melnik A.A., Odintsovo I.N., Martynova N.A. // Siberian Oncological Journal. - 2003 No. 1. - pp.56-69.]
15. Роль папилломавирусной инфекции в онкогинекологической патологии / Сафронникова Н.Р., Вишневский А. С., Мера
бишвили В.М. // Сб. Новые информационные технологии в онкологической статистике.- СПб.: 2021. - С.204-205.[The
role of papillomavirus infection in oncogynecological pathology / Safronnikova N.R., Vishnevsky A.S., Merabishvili V.M. // Col
lection of New information technologies in oncological statistics.- St. Petersburg: 2021. - pp.204-205.]
16. Трубина Т.Б. / Особенности диагностики и лечения фоновых и предраковых заболеваний шейки матки у женщин, пере
несших медицинский аборт // Трубина Т.Б. Здравоохранение Башкортостана, 2018. - №4. - С.59-61.[Trubina T.B. / Features
of diagnosis and treatment of back ground and precancerous diseases of the cervix in women who have undergone medical
abortion // Trubina T.B. Health care of Bashkortostan, 2018. - No. 4. - pp.59-61.]
17. Фролова И.И. Клинико-морфологические исследования дискератозов и предрака шейки матки // Фролова И.И., Бабиченко И.И. / Вопросы гинекологии, акушерства и перинатологии. - 2019. - т.2, №3.- С. 19-24.[Frolova I.I. Clinical and morphological studies of dyskeratoses and precancerous cervix // Frolova I.I., Babichenko I.I. / Questions of gynecology, obstetrics and perinatology. - 2019. - vol.2, No. 3.- pp. 19-24.]
18. Шаймарданова Г.И. Клинические проявления папилломавирусной инфекции гениталий у женщин. // Шаймарданова Г.
И., Савичева A.M., Максимов С.Я. Журнал акушерства и женских болезней. - 2021. Выпуск 2., том XLX - С.14-18. [Shai
mardanova G.I. Clinical manifestations of genital papillomavirus infection in women. // Shaimardanova G.I., Savicheva A.M.,
Maksimov S.Ya. Journal of Obstetrics and women's diseases. - 2021. Issue 2., volume XLX - p.14-18.
19. Шериз Ж. Профилактика рака шейки матки в районах с недостаточным обеспечением ресурсами здравоохранения //
Шериз Ж., Хердман К. Точка зрения. - перев. 2020.- т. 18 №1. - С. 1-7. [Sheriz Zh. Prevention of cervical cancer in areas with in sufficient provision of health resources // Sheriz J., Herdman K. Point of view. - transl. 2020. - vol. 18 No. 1. - pp. 1-7.]
20. Alphs H.H., Wu T.C., Roden R.B.S. Prevention and treatment of cervical cancer by vaccination. In: Bovicelli A, Giordano A,
Kurman RJ (eds.), Molecular pathology of gynecology cancer, Humana Press, Totowa, New Jersey, 2017;124–154.
21. Altobelli E., Lattanzi A. Cervical Carcinoma in the European Union: An Update on Disease Burden, Screening Program State of
Activation, and Coverage as of March 2014. Int. J. Gynecol. Cancer 2015, 474-483.
22. Anttila A., Ronco G. Description of the national situation of cervical cancer screening in the member states of the European
Union. Eur. J. Cancer 2019, 45, 2685-2708.
23. Apgar B.S., Kaufman A.J., Bettcher C. Gynecologic procedures:colposcopy, treatments for cervical intraepithelial neoplasia and
endometrial assessment. Am Fam Physician. 2018;87(12):836-43.
24. Asciutto K.C., Henic E., Darlin L. Follow up with HPV test and cytology as test of cure, 6 months after conization, is reliable.
Acta Obstet. Gynecol. Scand. 2016, 95,1251-1257.
25. Ayinde O.A., Omigbodun A.O., Ilesanmi A.O. Awareness of cervical cancer, Papanicolaou's smear and its utilisation among fema
le undergraduates in Ibadan. Afr J Reprod Health. 2017;8(3):68-80.
26. Bassal R., Schejter E., Bachar R. Recent trends of cervical cancer and Cervical Intraepithelial Neoplasia 3 (CIN3) in Israel.
Arch.Gynecol. Obstet. 2015, 292, 405-413.
27. Basu P., Meheus F., Chami Y. Management algorithms for cervical cancer screening and precancer treatment for resource-limited
settings. Int. J. Gynecol. Obstet.2017, 26-32.
28. Blumenthal P.D., Lauterbach M., Sellors J.W. Training for cervical cancer prevention programs in low-resource settings: focus
on visual inspection with acetic acid and cryotherapy. Int J Gynaecol Obstet Off Organ Int Fed Gynaecol Obstet. 2017;89 Suppl
2:S30-7.
29. Boiron, L., Joura E., Largeron N. Estimating the cost-effectiveness profile of a universal vaccination programme with a nine-
valent HPV vaccine in Austria. BMC Infect. Dis. 2016,16,153.
30. Boonlikit S. Correlation between Reid’s colposcopic index and histologic results from colposcopically directed biopsy in differ
entiating high-grade from low-grade squamous in traepithelial lesion at Rajavithi Hospital, Med Assoc Thai, 2021; 94(Suppl.2):
S59–65.
31. Borena W., Grunberger M., Widschwendter. Pre-vaccine eracervical human papillomavirus infection among screening population
of women in west Austria. BMC Public Health 2016,16, 889.
32. Bornstein J., Bentley J., Bosze P. Colposcopic terminology of the International Federation for Cervical Pathology and Colposcopy. Obstet Gynecol. 2022;120:166-72.
33. Campbell C., Kafwafwa S., Brown H. Use of thermo-coagulation as an alternative treatment modality in a ’screen and treat’ pro
gramme of cervical screening in rural Malawi. Int J Cancer 2016; 139:908-15.
34. Campos N.G., Maza M., Alfaro K. The comparative and cost-effectiveness of HPV- based cervical cancer screening algorithms
in El Salvador. Int J Cancer 2015;137:893-902.
35. Castanon A., Landy R., Cuzick J. Cervical Screening at Age 50-64 Years and the Risk of Cervical Cancer at Age 65 Years and
Older: Population-Based Case Control Study. PLoS Med. 2019,11, e1001585.
36. Castle P.E., Smith K.M., Davis T.E. Reliability of the Xpert HPV assay to detect high-risk human papillomavirus DNA in a col
poscopy referral population. Am J Clin Pathol 2015;143: 126-33.
37. Chirenje Z.M., Rusakaniko S., Kirumbi L. Situation analysis for cervical cancer diagnosis and treatment in east, central and
southern African countries. Bull World Health Organ 2021;79:127-32.
38. Clarke B., Chetty R. Postmodern cancer: the role of humanimmunodeficiency virus in uterine cervical cancer. MolPathol MP.
2022;55(1):19-24.
39. Clifford G.M., Smith J.S., Plummer M. Human papillo mavirus types in invasive cervical cancer worldwide: a meta-analysis. Br
J Cancer. 2018;88(1):63-73.
40. Collins S., Mazloomzadeh S., Winter H. High incidence of cervical human papillomavirus infection in women during their first
sexual relationship. BJOG Int J Obstet Gynaecol.2022;109(1):96-8.
41. Costa S., Venturoli S., Origoni M. Performance of HPV DNA testing in the follow-up after treatment of high-grade cervical le
sions, adenocarcinoma in situ (AIS) and microinvasive carcinoma. Ecancermedicalscience 2015, 9, 528.
42. Cunningham M.S., Davison C., Aronson K.J.HPV vaccine acceptability in Africa:a systematic review.Prev Med. 2021;69:274-9.
43. Cuschieri K., Bhatia R., Cruickshank M. HPV testing in the context of post-treatment follow up (test of cure). J. Clin.Virol. 2016, 76, S. 56-S61.
44. Cuzick J., Szarewski A., Cubie H. et al. Management of women who test positive for high-risk types of human papillomavirus:
The HART study. Lancet 2023, 362,1871-1876.
45. Dalla Palma P., Giorgi Rossi P., Collina G. et al. The risk of false-positive histology according to the reason for colpos copy re
ferral in cervical cancer screening: a blind revision of all histologic lesions found in the NTCC trial. Am J Clin Pathol, 2018; 12
9(1): 75–80.
46. de Freitas A.C., Coimbra E.C., Leitao Mda C.G. Molecular targets of HPV oncoproteins: potential biomarkers for cervical car
cinogenesis. Biochim Biophys Acta. 2020;1845(2):91-103.
47. De Thurah L., Bonde J., Lam J.U.H. Concordant testing results between various human papillomavirus assays in primary cervical cancer screening: Systematic review. Clin.Microbiol. Infect. 2018,29-36.
48. Denny L., Quinn M., Sankaranarayanan R. Chapter 8: Screening for cervical cancer in developing countries. Vaccine.2016;24
Suppl 3:S3/71-7.
49. Dijkstra M.G., van Niekerk D., Rijkaart D.C. Primary hrHPVDNA Testing in Cervical Cancer Screening: How to Manage Screen-Positive Women? A POBASCAM Trial Substudy. Cancer Epidemiol. Biomarkers Prev. 2017, 23,55-63.
50. Dobson S.R.M., McNeil S., Dionne M. Immunogenicity of 2doses of HPV vaccine in younger adolescents vs 3 doses in
young women:a randomized clinical trial. JAMA.2018; 30 9(17):1793-802.
51. Eze J.N., Umeora O.U., Obuna J.A. Cervical cancer awareness and cervical screening uptake at the Mater Misericordiae Hospital, Afikpo, Southeast Nigeria. Ann Afr Med. 2022;11 (4):238-43.
52. Ezechi O.C.,Gab-Okafor C.V.,Ostergren P.O. Willingness and acceptability of cervical cancer screening among HIV positive
Nigerian women. BMC Public Health. 2018;13 (1):46.
53. Goldie S.J., Gaffikin L., Goldhaber-Fiebert J.D. et al. Cost-effectiveness of cervical-cancer screening in five developing countries. N Engl J Med. 2015;353(20):2158-68.
1. Василевская Л.Н. Предраковые заболевания и начальные формы рака шейки матки // Василевская Л.Н., Винокур М.Л.,
Никитина Н.И., М.: Медицина: 2011. С.4-23. [Vasilevskaya L.N. Precancerous diseases and initial forms of cervical cancer //
Vasilevskaya L.N., Vinokur M.L., Nikitina N.I., M.: Medicine: 2011. pp.4-23.]
2. Волков В.Г. Современные возможности лечения папилломавирусной инфекции шейки матки // Волков В.Г., Захарова Т.
В. Вестник новых медицинских технологий. 2020.- т.7 № 2. - С. 79-81.[Volkov V.G. Modern possibilities of treatment of pa
pillomavirus infection of the cervix // Volkov V.G., Zakharova T.V. Bulletin of new medical technologies. 2020.- vol.7 No. 2. -
pp. 79-81.]
3. Гузенко Н.Н. Диагностика папилломавирусной инфекции человека (ВПЧ) и ее клиническое значение // Гузенко Н.Н. Ак
туальные проблемы здравоохранения областей Центральной России: сборник науч. тр.-Липецк, 2021. - Ч.1.- С.181-183.
[Guzenko N.N. Diagnostics of human papillomavirus infection (HPV) and its clinical significance // Guzenko N.N. Actual pro
blems of healthcare in the regions of Central Russia:collection of scientific tr.-Lipetsk, 2021. - Part 1.- pp.181-183.
4. Дубенский В.В. Урогенитальная папилломавирусная инфекция // Дубенский В.В. Российский журнал кожных и венери
ческих болезней. - 2015.- №5. - С.50-55. [Dubensky V.V. Urogenital papillomavirus infection // Dubensky V.V. Russian Journal
of Skin and Venereal Diseases.- 2015.- No.5. - pp.50-55.
5. Клинико-морфологические аспекты цервикальной папилломавирусной инфекции / Л. Ф. Коломиец, Л. Н. Уразова, Н. В.
Севастьянова, О. Н. Чуруксаева // Вопр. онкол. -2022. -Т.48, №1. - С.43-46. [Clinical and morphological aspects of cervical
papilloma virus infection / L. F. Kolomiets, L. N. Urazova, N. V. Sevastyanova, O. N. Churuksaeva // Vopr. oncol. -2022. -Vol.
48, No. 1. - pp.43-46.]
6. Козаченко В.П. / Диагностика и лечение эпителиальных дисплазий и преинвазивной карциномы шейки матки // Козаченко
В.П. Клин. лекции под ред. В. Н. Прилепской 2-е изд. М.: МЕДпресс, 2000. - С. 139-152. [Kozachenko V.P. / Diagnosis and
treatment of epithelial dysplasia and preinvasive cervical carcinoma // Kozachenko V.P. Clinical lectures edited by V. N. Prileps
kaya 2nd ed. M.: MEDpress, 2000. - Pp. 139-152.
7. Козаченко В.П. Современное состояние проблемы рака шейки матки // Козаченко В.П. Клин. лекции под ред. В.Н. При
лепской 2-е изд. // М.:МЕДпресс: 2000. - С.133-138. [Kozachenko V.P. The current state of the problem of cervical cancer //
Kozachenko V.P. Klin. lectures edited by V. N. Prilepskaya 2nd ed. // Moscow:MEDpress: 2000. - pp.133-138.
8. Коломиец Л. А. Генитальная папилломавирусная инфекция и рак шейки матки // Коломиец Л.А., Уразова Л.Н. Томск:
НТЛ, 2002. 100 с.[Kolomiets L. A. Genital papillomavirus infection and cervical cancer // Kolomiets L.A., Urazova L.N. Tomsk:
NTL, 2002. 100 p.]
9. Кустаров В.Н. Патология шейки матки // Кустаров В.Н., Линде В.А. СПб.: Изд. «Гиппократ», 2002. 144 с. [Kustarov
V.N. Pathology of the cervix // Kustarov V.N., Linde V.A. St. Petersburg: Publishing house "Hippocrates", 2002. 144 p.]
10. Ландеховский Ю.Д. Хирургическое лечение лейкоплакии шейки матки // Ландеховский Ю.Д., Бабичева И.А. Клин, лек
ции под ред. В.Н. Прилепской. 2-е изд.- М.:МЕДпресс 2000. - С.94-107. [Landekhovsky Yu.D. Surgical treatment of cervical
leukoplakia // Landekhovsky Yu.D., Babicheva I.A. Klin, lectures edited by V.N. Prilepskaya. 2nd ed.- Moscow: MEDpress 200
0. - pp.94-107.]
11. Манухин И.Б. Клиника, диагностика и лечение генитального герпеса у женщин //Манухин И.Б., Захарова Т.П. Клин, лек
ции под ред. В.Н. Прилепской 2-е изд.- М.:МЕДпресс 2000.- С. 229-239. [Manukhin I.B. Clinic, diagnosis and treatment of
genital herpes in women // Manukhin I.B., Zakharova T.P. Klin, lectures edited by V.N. Prilepskaya 2nd ed. - M.: MEDpress 20
00.- pp. 229-239.]
12. Марченко Л.A. Современные клинические аспекты эпидемиологии генитального герпеса // Марченко Л.А.Клин, лекции
под ред. В.Н. Прилепской 2-е изд.-М.: МЕДпресс 2000. - С.220-228.[Marchenko L.A. Modern clinical aspects of epidemiology
of genital herpes // Marchenko L.A. Klin, lectures edited by V.N. Prilepskaya 2nd ed.-M.: MEDpress 2000. - pp.220- 228.]
13. Полякова В.А. Онкогинекология //Полякова В.А. Москва:Изд-во «Медицинская книга», 2001. - С.66-105.[Polyakova V.A.
Oncogynecology // Polyakova V.A. Moscow: Publishing house "Medical Book",2001. - pp.66-105.]
14. Рак репродуктивных органов: эпидемиология, факторы риска / Писарева Л.Ф., Мельник А.А., Одинцова И.Н., Мартынова Н.А. // Сибирский онкологический журнал. - 2003 №1. - С.56-69.[Cancer of reproductive organs: epidemiology, risk factors Pisareva L.F., Melnik A.A., Odintsovo I.N., Martynova N.A. // Siberian Oncological Journal. - 2003 No. 1. - pp.56-69.]
15. Роль папилломавирусной инфекции в онкогинекологической патологии / Сафронникова Н.Р., Вишневский А. С., Мера
бишвили В.М. // Сб. Новые информационные технологии в онкологической статистике.- СПб.: 2021. - С.204-205.[The
role of papillomavirus infection in oncogynecological pathology / Safronnikova N.R., Vishnevsky A.S., Merabishvili V.M. // Col
lection of New information technologies in oncological statistics.- St. Petersburg: 2021. - pp.204-205.]
16. Трубина Т.Б. / Особенности диагностики и лечения фоновых и предраковых заболеваний шейки матки у женщин, пере
несших медицинский аборт // Трубина Т.Б. Здравоохранение Башкортостана, 2018. - №4. - С.59-61.[Trubina T.B. / Features
of diagnosis and treatment of back ground and precancerous diseases of the cervix in women who have undergone medical
abortion // Trubina T.B. Health care of Bashkortostan, 2018. - No. 4. - pp.59-61.]
17. Фролова И.И. Клинико-морфологические исследования дискератозов и предрака шейки матки // Фролова И.И., Бабиченко И.И. / Вопросы гинекологии, акушерства и перинатологии. - 2019. - т.2, №3.- С. 19-24.[Frolova I.I. Clinical and morphological studies of dyskeratoses and precancerous cervix // Frolova I.I., Babichenko I.I. / Questions of gynecology, obstetrics and perinatology. - 2019. - vol.2, No. 3.- pp. 19-24.]
18. Шаймарданова Г.И. Клинические проявления папилломавирусной инфекции гениталий у женщин. // Шаймарданова Г.
И., Савичева A.M., Максимов С.Я. Журнал акушерства и женских болезней. - 2021. Выпуск 2., том XLX - С.14-18. [Shai
mardanova G.I. Clinical manifestations of genital papillomavirus infection in women. // Shaimardanova G.I., Savicheva A.M.,
Maksimov S.Ya. Journal of Obstetrics and women's diseases. - 2021. Issue 2., volume XLX - p.14-18.
19. Шериз Ж. Профилактика рака шейки матки в районах с недостаточным обеспечением ресурсами здравоохранения //
Шериз Ж., Хердман К. Точка зрения. - перев. 2020.- т. 18 №1. - С. 1-7. [Sheriz Zh. Prevention of cervical cancer in areas with in sufficient provision of health resources // Sheriz J., Herdman K. Point of view. - transl. 2020. - vol. 18 No. 1. - pp. 1-7.]
20. Alphs H.H., Wu T.C., Roden R.B.S. Prevention and treatment of cervical cancer by vaccination. In: Bovicelli A, Giordano A,
Kurman RJ (eds.), Molecular pathology of gynecology cancer, Humana Press, Totowa, New Jersey, 2017;124–154.
21. Altobelli E., Lattanzi A. Cervical Carcinoma in the European Union: An Update on Disease Burden, Screening Program State of
Activation, and Coverage as of March 2014. Int. J. Gynecol. Cancer 2015, 474-483.
22. Anttila A., Ronco G. Description of the national situation of cervical cancer screening in the member states of the European
Union. Eur. J. Cancer 2019, 45, 2685-2708.
23. Apgar B.S., Kaufman A.J., Bettcher C. Gynecologic procedures:colposcopy, treatments for cervical intraepithelial neoplasia and
endometrial assessment. Am Fam Physician. 2018;87(12):836-43.
24. Asciutto K.C., Henic E., Darlin L. Follow up with HPV test and cytology as test of cure, 6 months after conization, is reliable.
Acta Obstet. Gynecol. Scand. 2016, 95,1251-1257.
25. Ayinde O.A., Omigbodun A.O., Ilesanmi A.O. Awareness of cervical cancer, Papanicolaou's smear and its utilisation among fema
le undergraduates in Ibadan. Afr J Reprod Health. 2017;8(3):68-80.
26. Bassal R., Schejter E., Bachar R. Recent trends of cervical cancer and Cervical Intraepithelial Neoplasia 3 (CIN3) in Israel.
Arch.Gynecol. Obstet. 2015, 292, 405-413.
27. Basu P., Meheus F., Chami Y. Management algorithms for cervical cancer screening and precancer treatment for resource-limited
settings. Int. J. Gynecol. Obstet.2017, 26-32.
28. Blumenthal P.D., Lauterbach M., Sellors J.W. Training for cervical cancer prevention programs in low-resource settings: focus
on visual inspection with acetic acid and cryotherapy. Int J Gynaecol Obstet Off Organ Int Fed Gynaecol Obstet. 2017;89 Suppl
2:S30-7.
29. Boiron, L., Joura E., Largeron N. Estimating the cost-effectiveness profile of a universal vaccination programme with a nine-
valent HPV vaccine in Austria. BMC Infect. Dis. 2016,16,153.
30. Boonlikit S. Correlation between Reid’s colposcopic index and histologic results from colposcopically directed biopsy in differ
entiating high-grade from low-grade squamous in traepithelial lesion at Rajavithi Hospital, Med Assoc Thai, 2021; 94(Suppl.2):
S59–65.
31. Borena W., Grunberger M., Widschwendter. Pre-vaccine eracervical human papillomavirus infection among screening population
of women in west Austria. BMC Public Health 2016,16, 889.
32. Bornstein J., Bentley J., Bosze P. Colposcopic terminology of the International Federation for Cervical Pathology and Colposcopy. Obstet Gynecol. 2022;120:166-72.
33. Campbell C., Kafwafwa S., Brown H. Use of thermo-coagulation as an alternative treatment modality in a ’screen and treat’ pro
gramme of cervical screening in rural Malawi. Int J Cancer 2016; 139:908-15.
34. Campos N.G., Maza M., Alfaro K. The comparative and cost-effectiveness of HPV- based cervical cancer screening algorithms
in El Salvador. Int J Cancer 2015;137:893-902.
35. Castanon A., Landy R., Cuzick J. Cervical Screening at Age 50-64 Years and the Risk of Cervical Cancer at Age 65 Years and
Older: Population-Based Case Control Study. PLoS Med. 2019,11, e1001585.
36. Castle P.E., Smith K.M., Davis T.E. Reliability of the Xpert HPV assay to detect high-risk human papillomavirus DNA in a col
poscopy referral population. Am J Clin Pathol 2015;143: 126-33.
37. Chirenje Z.M., Rusakaniko S., Kirumbi L. Situation analysis for cervical cancer diagnosis and treatment in east, central and
southern African countries. Bull World Health Organ 2021;79:127-32.
38. Clarke B., Chetty R. Postmodern cancer: the role of humanimmunodeficiency virus in uterine cervical cancer. MolPathol MP.
2022;55(1):19-24.
39. Clifford G.M., Smith J.S., Plummer M. Human papillo mavirus types in invasive cervical cancer worldwide: a meta-analysis. Br
J Cancer. 2018;88(1):63-73.
40. Collins S., Mazloomzadeh S., Winter H. High incidence of cervical human papillomavirus infection in women during their first
sexual relationship. BJOG Int J Obstet Gynaecol.2022;109(1):96-8.
41. Costa S., Venturoli S., Origoni M. Performance of HPV DNA testing in the follow-up after treatment of high-grade cervical le
sions, adenocarcinoma in situ (AIS) and microinvasive carcinoma. Ecancermedicalscience 2015, 9, 528.
42. Cunningham M.S., Davison C., Aronson K.J.HPV vaccine acceptability in Africa:a systematic review.Prev Med. 2021;69:274-9.
43. Cuschieri K., Bhatia R., Cruickshank M. HPV testing in the context of post-treatment follow up (test of cure). J. Clin.Virol. 2016, 76, S. 56-S61.
44. Cuzick J., Szarewski A., Cubie H. et al. Management of women who test positive for high-risk types of human papillomavirus:
The HART study. Lancet 2023, 362,1871-1876.
45. Dalla Palma P., Giorgi Rossi P., Collina G. et al. The risk of false-positive histology according to the reason for colpos copy re
ferral in cervical cancer screening: a blind revision of all histologic lesions found in the NTCC trial. Am J Clin Pathol, 2018; 12
9(1): 75–80.
46. de Freitas A.C., Coimbra E.C., Leitao Mda C.G. Molecular targets of HPV oncoproteins: potential biomarkers for cervical car
cinogenesis. Biochim Biophys Acta. 2020;1845(2):91-103.
47. De Thurah L., Bonde J., Lam J.U.H. Concordant testing results between various human papillomavirus assays in primary cervical cancer screening: Systematic review. Clin.Microbiol. Infect. 2018,29-36.
48. Denny L., Quinn M., Sankaranarayanan R. Chapter 8: Screening for cervical cancer in developing countries. Vaccine.2016;24
Suppl 3:S3/71-7.
49. Dijkstra M.G., van Niekerk D., Rijkaart D.C. Primary hrHPVDNA Testing in Cervical Cancer Screening: How to Manage Screen-Positive Women? A POBASCAM Trial Substudy. Cancer Epidemiol. Biomarkers Prev. 2017, 23,55-63.
50. Dobson S.R.M., McNeil S., Dionne M. Immunogenicity of 2doses of HPV vaccine in younger adolescents vs 3 doses in
young women:a randomized clinical trial. JAMA.2018; 30 9(17):1793-802.
51. Eze J.N., Umeora O.U., Obuna J.A. Cervical cancer awareness and cervical screening uptake at the Mater Misericordiae Hospital, Afikpo, Southeast Nigeria. Ann Afr Med. 2022;11 (4):238-43.
52. Ezechi O.C.,Gab-Okafor C.V.,Ostergren P.O. Willingness and acceptability of cervical cancer screening among HIV positive
Nigerian women. BMC Public Health. 2018;13 (1):46.
53. Goldie S.J., Gaffikin L., Goldhaber-Fiebert J.D. et al. Cost-effectiveness of cervical-cancer screening in five developing countries. N Engl J Med. 2015;353(20):2158-68.
